Recursion Expects Cash Runway to Extend Into 2029

Recursion expects cash to fund operations into 2029, including net proceeds from its October 2026 underwritten offering of common stock. The offering is expected to generate approximately $200 million in gross proceeds. Cash, cash equivalents and restricted cash totaled approximately $561 million as of September 30, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via (Ref. ID: 202610150822PRIMZONEFULLFEED9846511) on October 15, 2026, and is solely responsible for the information contained therein. (C)